[{"data":1,"prerenderedAt":-1},["ShallowReactive",2],{"health-study-detail:100635422":3},{"organization":4,"armGroups":7,"interventions":17,"overallOfficials":11,"centralContacts":23,"locations":29,"responsibleParty":98,"collaborators":100,"id":108,"slug":11,"hasResults":109,"nctId":110,"briefTitle":111,"officialTitle":111,"acronym":11,"eligibilityCriteria":112,"healthyVolunteers":109,"sex":113,"minAge":114,"maxAge":115,"enrollmentInfo":116,"targetDuration":11,"studyType":119,"phases":120,"briefSummary":122,"conditions":123,"keywords":127,"overallStatus":131,"whyStopped":11,"lastUpdateSubmitDate":132,"lastUpdatePostDateStruct":133,"startDateStruct":136,"completionDateStruct":138,"leadSponsor":140,"locationsCount":141},{"fullName":5,"class":6},"Union Hospital, Tongji Medical College, Huazhong University of Science and Technology","OTHER",[8,14],{"label":9,"type":10,"description":11,"interventionNames":12},"Goserelin group","EXPERIMENTAL",null,[13],"Drug: Goserelin",{"label":15,"type":16,"description":11,"interventionNames":11},"Control group","NO_INTERVENTION",[18],{"type":19,"name":20,"description":21,"armGroupLabels":22,"otherNames":11},"DRUG","Goserelin","Subcutaneous injection of 3.6 mg of goserelin acetate once, administered 1 to 3 days prior to allogeneic haematopoietic stem cell transplantation.",[9],[24],{"name":25,"role":26,"phone":27,"phoneExt":11,"email":28},"wei Shi","CONTACT","86-13207131315","496020121@qq.com",[30,47,62,68,83],{"facility":31,"status":11,"city":32,"state":33,"zip":34,"country":35,"cosmosGeoPoint":36,"geoPoint":41,"contacts":42},"The First Affiliated Hospital of Zhengzhou University","Zhengzhou","Henan","450000","China",{"type":37,"coordinates":38},"Point",[39,40],113.64861,34.75778,{"lat":40,"lon":39},[43],{"name":44,"role":26,"phone":45,"phoneExt":11,"email":46},"jie wei Cao","86-15093360671","15093360671@163.com",{"facility":48,"status":11,"city":49,"state":50,"zip":51,"country":35,"cosmosGeoPoint":52,"geoPoint":56,"contacts":57},"Tongji Hospital, Tongji Medical College, Huazhong University of Science and Technology","Wuhan","Hubei","430000",{"type":37,"coordinates":53},[54,55],114.26667,30.58333,{"lat":55,"lon":54},[58],{"name":59,"role":26,"phone":60,"phoneExt":11,"email":61},"yang Cao","86-13986142606","13986142606@163.com",{"facility":5,"status":11,"city":49,"state":50,"zip":51,"country":35,"cosmosGeoPoint":63,"geoPoint":65,"contacts":66},{"type":37,"coordinates":64},[54,55],{"lat":55,"lon":54},[67],{"name":25,"role":26,"phone":27,"phoneExt":11,"email":28},{"facility":69,"status":11,"city":70,"state":71,"zip":72,"country":35,"cosmosGeoPoint":73,"geoPoint":77,"contacts":78},"The First People's Hospital of Yunnan Province","Kunming","Yunnan","650000",{"type":37,"coordinates":74},[75,76],102.71833,25.03889,{"lat":76,"lon":75},[79],{"name":80,"role":26,"phone":81,"phoneExt":11,"email":82},"jie ya Wang","86-13211630338","13211630338@163.com",{"facility":84,"status":11,"city":85,"state":86,"zip":87,"country":35,"cosmosGeoPoint":88,"geoPoint":92,"contacts":93},"The First Affiliated Hospital, Zhejiang University School of Medicine","Hangzhou","Zhejiang","310000",{"type":37,"coordinates":89},[90,91],120.16142,30.29365,{"lat":91,"lon":90},[94],{"name":95,"role":26,"phone":96,"phoneExt":11,"email":97},"min yan Zhao","86-15858199217","15858199217@163.com",{"type":99,"investigatorFullName":11,"investigatorTitle":11,"investigatorAffiliation":11,"oldNameTitle":11,"oldOrganization":11},"SPONSOR",[101,103,104,106],{"name":102,"class":6},"Wuhan TongJi Hospital",{"name":31,"class":6},{"name":105,"class":6},"First Affiliated Hospital of Zhejiang University",{"name":107,"class":6},"The First People's Hospital of Yunnan","100635422",false,"NCT07552480","Clinical Study on the Preservation of Ovarian Function Following Hematopoietic Stem Cell Transplantation in Patients With Malignant Hematologic Diseases Using Goserelin","Inclusion Criteria:\n\n1\\. Patients with malignant hematologic disorders scheduled for allogeneic hematopoietic stem cell transplantation (allo-HSCT); 2. Female patients aged 14 to 50 years, within reproductive age, with regular menstrual cycles prior to transplantation; 3. Patients or their legal representatives voluntarily participate and sign informed consent forms, demonstrating ability to understand and comply with all study procedures and requirements; 4. Expected survival exceeding 1 year to ensure sufficient time for monitoring menstrual recovery.\n\nExclusion Criteria:\n\n1\\. Patients with severe dysfunction of vital organs such as the heart, liver, or kidneys, which may affect study outcomes or increase patient risk; 2. Patients with a history of allergy to goserelin or other related medications; 3. Patients who have already undergone menopause due to physiological or pathological factors; 4. Patients with a history of gynecological conditions (e.g., polycystic ovary syndrome, endometriosis) that may interfere with the assessment of menstrual recovery; 5. Patients currently participating in other clinical studies that may affect menstrual recovery; 6. Patients who refuse to participate in this clinical study.","FEMALE","14 Years","50 Years",{"count":117,"type":118},64,"ESTIMATED","INTERVENTIONAL",[121],"NA","This study is a prospective, multicenter, randomized controlled clinical trial planned to enroll 64 female patients with malignant hematologic diseases aged 14-50 years who are scheduled to undergo allogeneic hematopoietic stem cell transplantation (allo-HSCT). Patients will be divided into two groups based on the use of myeloablative conditioning: the myeloablative conditioning (MAC) group and the non-MAC conditioning group. The non-MAC group refers to a primary conditioning regimen where the main conditioning agents-busulfan (Bu) ≤ 6.4 mg\u002Fkg, melphalan (Mel) ≤ 140 mg\u002Fm², and thiotepa ≤ 10 mg\u002Fkg-are combined. Patients receiving this primary chemotherapy regimen will be assigned to the MAC group. Within each group (MAC or non-MAC), patients were randomly assigned 1:1 to either the experimental group (goserelin prophylaxis) or the control group using a random number table. The experimental group received a single 3.6 mg subcutaneous injection of goserelin 1-3 days prior to conditioning, in addition to the standard transplantation regimen. The control group did not receive goserelin prophylaxis. The primary endpoint was menstrual recovery rate at 6 months post-transplantation. Secondary endpoints included: incidence of premature ovarian insufficiency (POI); ovarian reserve function markers: anti-Müllerian hormone (AMH), follicle-stimulating hormone (FSH), luteinizing hormone (LH), estradiol (E2) levels; other reproductive indicators: ovarian volume, endometrial thickness; Neutrophil\u002Fplatelet engraftment time; Complications: incidence of acute\u002Fchronic graft-versus-host disease (aGVHD\u002FcGVHD), EBV\u002FCMV infection rates; Disease recurrence rate; Transplant-related mortality; Adverse event (AE) occurrence. This study aims to evaluate the efficacy and safety of goserelin in improving ovarian function following hematopoietic stem cell transplantation in patients with malignant hematologic diseases.",[124,125,126],"Allogeneic Haematopoietic Stem Cell Transplantation","Malignant Hematologic Disease","Ovarian Insufficiency",[128,129,130],"Malignant Hematologic Diseases","Allogeneic haematopoietic stem cell transplantation","Ovarian insufficiency","NOT_YET_RECRUITING","2026-04-20",{"date":134,"type":135},"2026-04-27","ACTUAL",{"date":137,"type":118},"2026-05-01",{"date":139,"type":118},"2027-10-01",{"name":5,"class":6},5]